Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
- 1 February 2002
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 8 (2), 128-135
- https://doi.org/10.1038/nm0202-128
Abstract
Conventional immunosuppressive drugs have been used effectively to prevent immunologic rejection in organ transplantation. Individuals taking these drugs are at risk, however, for the development and recurrence of cancer. In the present study we show that the new immunosuppressive drug rapamycin (RAPA) may reduce the risk of cancer development while simultaneously providing effective immunosuppression. Experimentally, RAPA inhibited metastatic tumor growth and angiogenesis in in vivo mouse models. In addition, normal immunosuppressive doses of RAPA effectively controlled the growth of established tumors. In contrast, the most widely recognized immunosuppressive drug, cyclosporine, promoted tumor growth. From a mechanistic perspective, RAPA showed antiangiogenic activities linked to a decrease in production of vascular endothelial growth factor (VEGF) and to a markedly inhibited response of vascular endothelial cells to stimulation by VEGF. Thus, the use of RAPA, instead of cyclosporine, may reduce the chance of recurrent or de novo cancer in high-risk transplant patients.Keywords
This publication has 29 references indexed in Scilit:
- Synergistic Cooperation between Hypoxia and Transforming Growth Factor-β Pathways on Human Vascular Endothelial Growth Factor Gene ExpressionPublished by Elsevier BV ,2001
- Identification of Tyrosine Residues in Vascular Endothelial Growth Factor Receptor-2/FLK-1 Involved in Activation of Phosphatidylinositol 3-Kinase and Cell ProliferationPublished by Elsevier BV ,2001
- Rapamycin in transplantation: A review of the evidenceKidney International, 2001
- Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive RegimenThe New England Journal of Medicine, 2000
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJCI Insight, 2000
- DIFFERENTIAL EFFECTS OF SHORT-TERM ACE- AND AT1-RECEPTOR INHIBITION ON POSTISCHEMIC INJURY AND LEUKOCYTE ADHERENCE IN VIVO AND IN VITROShock, 2000
- Regulation of Mammalian O2Homeostasis by Hypoxia-Inducible Factor 1Annual Review of Cell and Developmental Biology, 1999
- QUANTIFICATION OF MURINE CYTOKINE mRNAs USING REAL TIME QUANTITATIVE REVERSE TRANSCRIPTASE PCRCytokine, 1999
- Recurrence of Bronchioloalveolar Carcinoma in Transplanted LungsThe New England Journal of Medicine, 1999
- The mechanism of action of cyclosporin A and FK506Immunology Today, 1992